Clinical Trial Update: Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Cu-64-PSMA-I&T for PET imaging of metastatic PSMA-positive lesions in men with prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cu-64-PSMA-I&T (Cu-64 labeled PSMA-I&T radiotracer)

Snippet

Sponsor: Curium US LLC | Conditions: Metastasis From Malignant Tumor of Prostate (Disorder) | Phase 2 | Status: COMPLETED | Results posted: 2025-01-24